W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in…
Miasta: WarszawaWiek: od 18 latSponsor: Grifols Therapeutics LLC
W Polsce: ZakończoneNa świecie: RekrutujeFaza III
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
Miasta: MysłowiceWiek: od 18 latSponsor: Takeda Development Center Americas Inc.
RekrutujeFaza III
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
Miasta: Mysłowice, Warszawa, ŚląskieWiek: od 18 latSponsor: Takeda Development Center Americas Inc.
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency
Miasta: Kraków, WarszawaWiek: od 18 latSponsor: Grifols Therapeutics LLC